Compare AbbVie Inc (ABBV) vs OneSpan Inc (OSPN) Price & Performance

AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.

The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.

OneSpan (OSPN) trades at $15.09, up 4.5% today, showing strong momentum despite trading above the analyst consensus price target of $13.50. The stock exhibits bullish technical signals with recent earnings beats and robust profitability metrics including 28.5% net income margin and 27.8% ROE. Recent corporate developments include leadership team expansion and digital credentials launch, signaling growth initiatives.

The outlook remains positive with strong analyst support (67% buy ratings) and attractive valuation multiples (P/E 8.3x), though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains earnings momentum, while execution risks and market volatility present headwinds for investors.